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Abstract
Background: Although high-density lipoprotein (HDL) and non-HDL cholesterol have
opposite associations with coronary heart disease, multi-country reports of lipid trends
only use total cholesterol (TC). Our aim was to compare trends in total, HDL and non-
HDL cholesterol and the total-to-HDL cholesterol ratio in Asian and Western countries.
Methods: We pooled 458 population-based studies with 82.1 million participants in 23
Asian and Western countries. We estimated changes in mean total, HDL and non-HDL
cholesterol and mean total-to-HDL cholesterol ratio by country, sex and age group.
Results: Since 1980, mean TC increased in Asian countries. In Japan and South Korea,
the TC rise was due to rising HDL cholesterol, which increased by up to 0.17 mmol/L per
decade in Japanese women; in China, it was due to rising non-HDL cholesterol. TC de-
clined in Western countries, except in Polish men. The decline was largest in Finland and
Norway, at 0.4 mmol/L per decade. The decline in TC in most Western countries was
the net effect of an increase in HDL cholesterol and a decline in non-HDL cholesterol,
with the HDL cholesterol increase largest in New Zealand and Switzerland. Mean
total-to-HDL cholesterol ratio declined in Japan, South Korea and most Western coun-
tries, by as much as 0.7 per decade in Swiss men (equivalent to 26% decline in coro-
nary heart disease risk per decade). The ratio increased in China.
Conclusions: HDL cholesterol has risen and the total-to-HDL cholesterol ratio has de-
clined in many Western countries, Japan and South Korea, with only a weak correlation
with changes in TC or non-HDL cholesterol.
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Introduction
Blood cholesterol is one of the most important risk factors
for coronary heart disease (CHD).1–4 Population-level data
on blood cholesterol are an important input for planning
and evaluating the impacts of public health interventions
and treatment programmes on entire countries and com-
munities. Comparable data in different countries can help
to benchmark success in lowering cholesterol across coun-
tries and to understand the reasons behind different trends,
both those that were a result of active interventions and
unplanned secular changes in nutrition and health
behaviours.
Multi-country reporting of lipid trends has so far been
based on total cholesterol (TC).5,6 However, high-density
lipoprotein (HDL) and non-HDL or low-density lipopro-
tein (LDL) cholesterol have opposite associations with
CHD1,2 and can respond differently to changes in diet and
treatment. Currently, there are no comparable cross-
country data on lipid fractions, including LDL and HDL
cholesterol, and the total-to-HDL cholesterol ratio; only
studies in individual countries have reported such trends.7–27
To fill this important gap, we used population-based data to
analyse and compare long-term changes in TC, HDL and
non-HDL cholesterol, and the total-to-HDL cholesterol ra-
tio in Western and Asian countries over a period of more
than 30 years.
Methods
Primary outcomes
For this analysis, we used mean total, HDL and non-HDL
cholesterol and mean total-to-HDL cholesterol ratio as pri-
mary outcomes. The hazardous effects of blood cholesterol
on CHD were first established in the Framingham Study,
focusing on TC.28 However, physiological studies29 and
subsequent analyses of the Framingham Study30 found that
the fractions of blood cholesterol carried by different
lipoproteins and lipid ratios affect CHD risk differentially,
and at times in opposite directions. Pooled analyses of ob-
servational epidemiological studies have established that
CHD risk is associated directly with LDL and non-HDL
cholesterol and inversely with HDL cholesterol.1,2 As a re-
sult, lipid ratios such as the total-to-HDL cholesterol ratio,
which incorporates information on lipid fractions with op-
posite associations, have emerged as a particularly good
predictor of CHD risk in clinical and epidemiological
applications.1,2 Randomized clinical trials have also shown
that lowering LDL and non-HDL cholesterol lowers CHD
risk.31–34 In contrast, the results of observational studies
on HDL cholesterol have not been replicated in random-
ized trials or in Mendelian randomization studies.35–38
We used non-HDL cholesterol rather than LDL choles-
terol because most studies in our analysis had measured TC
and HDL cholesterol, from which non-HDL cholesterol
can be calculated by subtraction. In contrast, LDL choles-
terol was directly measured in only 13% of studies. When
LDL cholesterol is not directly measured, its estimation
requires data on triglycerides, which were available in only
61% of studies. Further, the most commonly used estima-
tion method, i.e. the Friedewald equation, can be inaccu-
rate.39 We found that non-HDL and LDL cholesterol were
correlated in studies with data on both variables (r¼ 0.93)
(Supplementary Figure 1, available as Supplementary data
at IJE online). Non-HDL cholesterol predicts CHD risk at
least as well as LDL cholesterol40,41 because it includes cho-
lesterol in LDL, lipoprotein(a), intermediate-density lipo-
protein, very-low-density lipoprotein and lipoprotein
remnants, and is thus a simple measure of cholesterol con-
tent within all atherogenic lipoproteins.
Countries analysed
Our analyses included Asian and Western countries that
had at least five population-based studies (or at least three
if the studies were nationally representative) in the Non-
Communicable Disease Risk Factor Collaboration (NCD-
Key Messages
• Total cholesterol (TC) has increased in Asian countries. In Japan and South Korea, the TC rise was largely due to an
increase in HDL cholesterol; in China, it was due to a rise in non-HDL cholesterol.
• The observed decline in TC in most Western countries was the net effect of an increase in HDL cholesterol and a de-
cline in non-HDL cholesterol.
• The total-to-HDL cholesterol ratio has declined in many Western countries, Japan and South Korea, with only a weak
correlation with changes in TC or non-HDL cholesterol.
• Countries’ comparative performance in reducing the risks associated with blood lipids is only partially captured by
trends in TC.
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RisC) database, as described below, with measurement of
total and HDL cholesterol over a period of at least 15 years
from 1970 onwards, with at least one data source after
2005. Twenty-one countries, listed below, met these
criteria:
• Nordic countries: Finland, Iceland and Norway.
• Eastern central Europe: Czech Republic, Lithuania,
Poland and Slovakia.
• Western central Europe: Belgium, Germany and
Switzerland.
• Southern Europe: France, Italy and Spain.
• High-income English-speaking countries: Australia,
Canada, New Zealand, UK and USA.
• East and southeast Asia: China, Japan and South Korea.
Two additional countries, Sweden and Thailand, had
sufficient data on TC but not on HDL cholesterol and
were included in TC analysis only.
Data sources
We used studies that had measured cholesterol in represen-
tative samples of the national population or of one or more
subnational regions and communities. We used a database
on cardiometabolic risk factors collated by NCD-RisC.
NCD-RisC is a worldwide network of health researchers
and practitioners whose aim is to document systematically
worldwide trends and variations in NCD risk factors.42–45
The database was collated through multiple routes for iden-
tifying and accessing data. We accessed publicly available
population-based measurement surveys [e.g. Demographic
and Health Surveys (DHS), Global School-based Student
Health Surveys (GSHS), the European Health Interview and
Health Examination Surveys (EHIS and EHES) and those
available via the Inter-university Consortium for Political
and Social Research (ICPSR)]. We requested, via the World
Health Organization (WHO) and its regional and country
offices, help with identification and access to population-
based surveys from ministries of health and other national
health and statistical agencies. Requests were also sent via
the World Heart Federation to its national partners. We
made similar requests to the co-authors of an earlier pooled
analysis of cardiometabolic risk factors5,46–48 and invited
them to reanalyse data from their studies and join NCD-
RisC. Finally, to identify major sources not accessed
through the above routes, we searched and reviewed pub-
lished studies as detailed previously42–44 and invited all eligi-
ble studies to join NCD-RisC.
Anonymized individual record data from sources in-
cluded in NCD-RisC were reanalysed by the Pooled
Analysis and Writing Group or by data holders according
to a common protocol. Within each survey, we included
participants aged 18 years and older who were not preg-
nant. We dropped participants with implausible choles-
terol levels (defined as TC <1.75 or >20 mmol/L; HDL
cholesterol <0.4 or >5 mmol/L; TC values < HDL values)
(<0.1% of all subjects). To ensure summaries were pre-
pared according to the study protocol, the Pooled Analysis
and Writing Group provided computer code to NCD-RisC
members who requested assistance. All submitted data
were checked by at least two independent members of the
Pooled Analysis and Writing Group. Questions and clarifi-
cations were discussed with NCD-RisC members and re-
solved before data were incorporated into the database.
Finally, we incorporated all nationally representative data
from sources that were identified but not accessed via the
above routes, by extracting summary statistics from pub-
lished reports. Data were extracted from published reports
only when reported by sex and in age groups no wider
than 20 years. We also used data from a previous global
data pooling study5 when such data had not been accessed
through the routes described.
All NCD-RisC members are asked periodically to re-
view the list of sources from their country, to suggest addi-
tional sources not in the database and to verify that the
included data meet the inclusion criteria listed below and
are not duplicates. The NCD-RisC database is continu-
ously updated through this contact with NCD-RisC mem-
bers and all the above routes. For this paper, we used data
from the NCD-RisC database for the 23 countries included
in the analysis, for years 1970–2018 and ages 40–79 years.
Data inclusion and exclusion
Data sources were included in the NCD-RisC lipids data-
base if:
• measured data on total, LDL, HDL cholesterol or trigly-
cerides were available;
• study participants were 10 years of age or older;
• data were collected using a probabilistic sampling
method with a defined sampling frame;
• data were from population samples at the national, sub-
national (i.e. covering one or more subnational regions,
more than three urban communities or more than five ru-
ral communities) or community level.
We excluded all data sources that included only hyper-
cholesterolemia or dyslipidaemia diagnosis history or med-
ication status without measurement of at least one of the
above biomarkers. We also excluded data sources on popu-
lation subgroups whose lipid profile may differ systemati-
cally from the general population, including:
• studies that had included or excluded people based on
their health status or cardiovascular risk;
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• studies whose participants were only ethnic minorities;
• specific educational, occupational or socio-economic
subgroups, with the exception noted below; and
• those recruited through health facilities, with the excep-
tion noted below.
We used data whose sampling frame was health insur-
ance schemes in countries where at least 80% of the popu-
lation were insured. Finally, we used data collected
through general practice and primary care systems in high-
income and central European countries with universal in-
surance because contact with the primary care systems
tends to be as good as, or better than, response rates for
population-based surveys.
We used data sources regardless of fasting status be-
cause the differences between fasting and non-fasting
measurements are negligible for our primary outcomes.49
From the CDC-NHLBI Lipid Standardization Program in
the 1950s, there has been an understanding of the need for,
and systematic efforts to achieve, standardization of lipid
measurements. The difference between any standardized
method and the CDC Reference method should be less
than 3% for TC and less than 5% for HDL cholesterol
(less than 10% before the mid-1990s).50 More than three-
quarters of the studies in our analysis participated in a lipid
standardization programme (Supplementary Table 1 and
Supplementary Figure 2, available as Supplementary data
at IJE online). A summary of data available by country is
shown in Supplementary Table 2, available as
Supplementary data at IJE online, and characteristics of
each study are shown in Supplementary Table 1, available
as Supplementary data at IJE online.
We extracted data for ages 40–79 years because people
aged below 40 years have a lower cardiovascular risk and
because data in older ages were available in fewer surveys.
CHD mortality increases with age whereas hazard ratios
for the effects of cholesterol on CHD decrease with age.1,2
As a result, a larger share of CHD deaths are attributable
to elevated cholesterol in middle-older ages, but the num-
ber of cholesterol-attributable deaths continues to increase
with age.4 We present results for 40–59 years as the pri-
mary analysis because data on these age groups were avail-
able for all countries included in the analysis. To
investigate the role of age in our findings, we compared
results for ages 40–59 years to those of 60–79 years in
countries with data for the entire age range of 40–79 years.
Statistical methods
For each study, we calculated mean total, HDL and non-
HDL cholesterol and mean total-to-HDL cholesterol ratio by
sex and 10-year age groups. The total-to-HDL cholesterol ra-
tio was calculated using individual records before averaging
for each sex and age group. All analyses incorporated appro-
priate complex survey design and survey sample weights in
calculating age- and sex-specific means.
For each primary outcome and for each country, sex
and age group, we calculated average annual change over
the entire period of data availability by fitting a linear re-
gression with the study-specific means as the dependent
variable and year as the independent variable. Each data
point was weighted by the inverse of the square of its stan-
dard error, so that larger studies had more influence on the
estimated change. We multiplied the slope of the fitted line
by 10 to calculate average change per decade. We also
used the fitted line to estimate total, HDL and non-HDL
cholesterol and the total-to-HDL cholesterol ratio values
for a consistent period of 1980–2015 for all countries. For
countries with data starting before 1980 and/or ending af-
ter 2015, this is equivalent to using the fitted line to inter-
polate for 1980 and/or 2015; for those with data starting
after 1980 and/or ending before 2015, values for 1980
and/or 2015 were extrapolated using the fitted line. In a
sensitivity analysis, we fitted a non-linear (LOESS) regres-
sion to examine by how much our results are influenced by
use of linear trend. For each primary outcome and for each
country, results were calculated by 10-year age groups,
separately for men and women, and then age-standardized
into two age bands (40–59 and 60–79 years) by taking a
weighted average of age-specific results using weights from
the WHO standard population. Analyses were performed
in R version 3.4.0 (The R Foundation for Statistical
Computing).
Results
Data availability
We used 438 population-based studies, collected from 1970 to
2018 in 21 countries that met our inclusion criteria for TC as
well as lipid fractions. An additional 20 studies were used for
analysis of TC in two additional countries (Thailand and
Sweden). Together, these studies included blood lipid measure-
ments in 82.1 million participants, 79million of whom were
aged 40–79years. The number of data sources ranged from 5
in Slovakia to 56 in Japan. The average time between the first
and last studies in a country was around three decades. For the
primary analysis, we used 425 studies with data for ages 40–
59years. All these 425 studies had data on TC. In the 21 coun-
tries included in the analysis of lipid fractions, 368 of 405 stud-
ies (90.9%) had data on HDL cholesterol and 367 (90.6%)
on the total-to-HDL cholesterol ratio. Details of data availabil-
ity by country and characteristics of each study are shown in
Supplementary Tables 1 and 2, available as Supplementary
data at IJE online.
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Total cholesterol
Mean TC declined in men and women aged 40–59 years in
most Western countries, except in Polish men, whose TC
was about the same at the beginning and end of the analysis
period (Figure 1). The absence of long-term change in
Poland was a result of a rise in mean TC until the late
1990s, followed by a decline (Supplementary Figure 3,
available as Supplementary data at IJE online). In both
sexes, the decline was larger in Nordic countries and central
Europe than in English-speaking countries and southern
Europe. The TC decline in men ranged from<0.1 mmol/L per
decade in Lithuania, New Zealand and France to
0.4 mmol/L per decade in Norway, Finland and Belgium.
In women, the range was from <0.1 mmol/L per decade in
Poland, France and Italy to 0.4 mmol/L per decade in
Finland, Norway and Belgium. TC increased in all four
Asian countries, with the largest increase in China and
Thailand, by 0.3 mmol/L per decade. Despite this rise,
Chinese women (but not men) still had the lowest estimated
mean TC of all 23 countries in 2015 (5.0 mmol/L)
(Supplementary Figure 4, available as Supplementary data
at IJE online). The highest mean TCs in 2015 were those in
Lithuanian and French men and Thai women, all above
5.7 mmol/L.
HDL and non-HDL cholesterol
Among the three Asian countries with data on lipid frac-
tions, the rise in mean TC in Japan and South Korea was
largely due to an increase in mean HDL cholesterol, which,
among Japanese and South Korean women, was offset
partly by a decline in non-HDL cholesterol (Figure 2). The
rise in HDL cholesterol ranged from 0.04 mmol/L per de-
cade in South Korean men to 0.17 mmol/L per decade in
Japanese women. In contrast, the TC rise in China was due
to an increase in non-HDL cholesterol whereas HDL cho-
lesterol remained unchanged in women and increased
slightly in men.
The decline in mean TC in many Western countries was
the net effect of a decline in non-HDL cholesterol and an in-
crease in HDL cholesterol (Figure 2). The key exceptions
were men and women in Germany and Norway, and men
in the Czech Republic and Slovakia, where both HDL and
non-HDL cholesterol declined. Similar to TC, mean non-
HDL cholesterol generally declined more in Nordic coun-
tries and central Europe than in English-speaking and
southern European countries. The largest rise in mean HDL
cholesterol occurred in New Zealand and Switzerland, by
0.10–0.15 mmol/L per decade in the two sexes.
The change in mean HDL cholesterol and change in
mean non-HDL cholesterol were not correlated (r¼ –0.004
for men and –0.07 for women) (Figure 3). In 2015, the low-
est levels of mean non-HDL cholesterol were those in China
and Belgium for men (3.7 mmol/L) and in Iceland for
women (3.3 mmol/L) (Supplementary Figure 5, available as
Supplementary data at IJE online). The highest were in
France: 4.4 mmol/L for men and 4.0 mmol/L for women.
Total-to-HDL cholesterol ratio
Mean total-to-HDL cholesterol ratio declined in most
Western countries, by as much as 0.7 per decade in Swiss
men and 0.5 per decade in New Zealand and Swiss
women (Figure 4). The ratio changed little in Slovakian
men. In Asia, China experienced a rise in mean total-to-
HDL cholesterol ratio because of the above-mentioned
non-favourable changes in lipid fractions. In contrast, de-
spite the rise in mean TC, the total-to-HDL cholesterol ra-
tio declined in Japan and South Korea because HDL
cholesterol increased by a larger proportion than did TC.
The change in mean total-to-HDL cholesterol ratio was
only moderately correlated with the change in mean TC
(correlation coefficient¼ 0.52 for men and 0.53 for
women) (Figure 5). Japan and South Korea were particu-
larly notable in having had a rise in TC but a decline in the
total-to-HDL cholesterol ratio, while Norway, Germany
and men in Slovakia had declining TC with little change in
the total-to-HDL cholesterol ratio. In 2015, the lowest ra-
tio was that of Japanese women (2.9) and Japanese men
(3.7) (Supplementary Figure 6, available as Supplementary
data at IJE online).
Results for people aged 60–79 years
Results in people aged 60–79 years were moderately to
strongly correlated with those aged 40–59 years (Figure 6
and Supplementary Figure 3, available as Supplementary
data at IJE online). In virtually all countries, mean TC,
non-HDL cholesterol and total-to-HDL cholesterol ratio
declined more in these older age groups than in people
aged 40–59 years. The decline advantage in older ages was
particularly evident for Australia and the UK, where
women and men aged 60–79 years experienced a decline in
non-HDL cholesterol twice as large as those aged 40–
59 years. The change in mean HDL cholesterol was larger
in older ages in some countries and smaller in others, indi-
cating that its change may be due to factors that are at least
partly different from those affecting non-HDL cholesterol.
Discussion
By conducting a comparative analysis of changes in TC
and lipid fractions and ratios, we found varying rates of
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Figure 1. Change per decade in mean total cholesterol by sex in people aged 40–59 years. Results for each country apply to its period of total choles-
terol data availability (Supplementary Table 2, available as Supplementary data at IJE online). See Supplementary Table 3, available as
Supplementary data at IJE online, for numerical results and 95% confidence intervals.
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Figure 2. Change per decade in mean (A) HDL and (B) non-HDL cholesterol by sex in people aged 40–59 years. Results for each country apply to its pe-
riod of HDL and non-HDL cholesterol data availability (Supplementary Table 2, available as Supplementary data at IJE online). See Supplementary
Table 4, available as Supplementary data at IJE online, for numerical results and 95% confidence intervals.
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Figure 2. Continued.
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decline in TC in Western countries and a rise in Asian coun-
tries, leading to an overall convergence in TC among these
countries. Underlying this convergence were more heteroge-
neous trends in HDL and non-HDL cholesterol, with HDL
cholesterol rising in more than half the countries included
in the analysis. The diverse trends in HDL and non-HDL
cholesterol resulted in substantial cross-country variation in
trends for mean total-to-HDL cholesterol ratio, with the ra-
tio declining in most countries, but increasing in China.
Our findings on TC trends are largely consistent with
prior multi- and single-country reports. Differences from
previous studies—e.g. in some countries that participated
in the MONICA Project,6 Poland21 and Switzerland24—
mostly arise because our study covered a longer period and
used a larger number of data sources. Fewer studies have
reported trends in lipid fractions and, to our knowledge,
none has done so consistently across countries. Studies that
have reported trends in lipid fractions for a period longer
than 15 years8,11,16,18–20,25–27 have found changes in non-
HDL cholesterol (or in LDL cholesterol for some studies)
that were consistent with our results.
The observed decline in non-HDL cholesterol in
Western countries is likely to have been mostly due to
changes in diet—especially the replacement of saturated
with unsaturated fats and reduction in trans-fats.8,20,51
Statins have also been widely used in high-risk patients
since the 1990s26,52 and may have helped lower the popu-
lation mean, especially in older ages. In the majority of
countries in our analysis, the decline in non-HDL choles-
terol started in the 1980s, before statins were widely used.
Further, we observed a decline in non-HDL cholesterol in
men and women aged 40–49 years, among whom statin
use is relatively low. Nonetheless, the higher use of statins
in older ages may at least partly explain the larger decline
in non-HDL cholesterol observed in those aged 60–
79 years.26,53
Dietary changes in Western countries contrast with the
substantial rise in consumption of animal fats in China,54
where statin use remains low.55 Focusing on non-HDL
cholesterol alone, however, conceals important changes in
HDL cholesterol and the total-to-HDL cholesterol ratio.
Although HDL cholesterol does not have a dominant non-
genetic determinant, it is affected adversely (i.e. is lower)
by adiposity, type 2 diabetes, intake of trans-fats and car-
bohydrates, especially those with a high glycaemic index,
smoking and the use of some drugs (e.g. b-blockers, ana-
bolic steroids).56–63 Conversely, increases in physical activ-
ity, alcohol consumption, total fat intake and oestrogens
increase HDL cholesterol.56,57,59–63 A decrease in carbohy-
drate intake and an increase in fat intake may have con-
tributed to the increase in HDL cholesterol in Japan,64,65
South Korea62,66 and Switzerland,67 whereas declines in
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Figure 3. Change per decade in mean non-HDL vs HDL cholesterol in people aged 40–59 years. Results for each country apply to its period of HDL and
non-HDL cholesterol data availability (Supplementary Table 2, available as Supplementary data at IJE online). See Supplementary Table 4, available
as Supplementary data at IJE online, for numerical results and 95% confidence intervals. AUS, Australia; BEL, Belgium; CAN, Canada; CHE,
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Figure 4. Change per decade in mean total-to-HDL cholesterol ratio by sex in people aged 40–59 years. Results for each country apply to its period of
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carbohydrate intake and smoking may have contributed to
the rise in the USA26 and some other countries. In contrast,
an increase in carbohydrate intake67 and a decline in alco-
hol consumption68 have been observed in Germany, where
we observed a slight decline in HDL cholesterol. The de-
cline in smoking in most Western countries may have also
contributed to the observed increase in HDL cholesterol.
The strengths of our study include its novel scope of
comparing lipid fractions across countries and using a
large number of high-quality population-based studies
over more than three decades. Such comprehensive data
allowed us to document a significant rise in HDL choles-
terol, which is considered difficult to change, in a number
of Western and Asian countries as a contributor to the de-
cline in the total-to-HDL cholesterol ratio. A multi-
country study, such as ours, is also affected by some limita-
tions. Clinical trials of drugs that raise HDL cholesterol
and genetic and epidemiologic studies have shown the
complexity of the relationship between HDL cholesterol,
HDL particles and cardiovascular and other dis-
eases.35,37,38,69 We used HDL and non-HDL cholesterol
because there were significantly more data available than
on LDL cholesterol and because the total-to-HDL choles-
terol ratio is commonly used in clinical practice. We did
not analyse trends in different HDL particles because this
information is not available in most population-based
health surveys and because it is not commonly used to
make clinical decisions. For the same reason, we also did
not analyse emerging lipid markers such as apolipoprotein
B and apolipoprotein A-I.56,70 We used the average change
per decade, estimated in a linear model, which has the ad-
vantage of being parsimonious, but trends in some coun-
tries may be non-linear. When we fitted a non-linear
LOESS regression (Supplementary Figure 3, available as
Supplementary data at IJE online), the estimated average
decadal change was similar to the estimates from the linear
model in most countries. Almost 80% of the studies in our
analysis had used enzymatic methods for measuring TC,
which have been well standardized since at least the 1980s.
Although methods to measure HDL cholesterol have
evolved over time—chemical precipitation methods to sep-
arate HDL and, more recently, homogeneous assays71—
more than three-quarters of the studies in our analysis par-
ticipated in a lipid standardization programme
(Supplementary Figure 2, available as Supplementary data
at IJE online). A rise in HDL cholesterol was also seen in
countries and over periods where measurement methods
did not change. Nonetheless, the observed changes in HDL
cholesterol in some countries were in the same order of
magnitude to which laboratories’ accuracies can be stan-
dardized. Although most studies had measured cholesterol
in serum, 11% had used plasma. Adjusting for plasma-
serum differences had little impact on our results and did
not change our conclusions (Supplementary Figure 7,
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available as Supplementary data at IJE online) because
cholesterol measured in plasma and serum differ by only
about 3%.50 Finally, although all our data were from sam-
ples of the general population, 40% came from
community-based studies. In some countries, community-
based studies came from the same community in different
years; in others, studies were from different parts of the
same country, which led to additional variability in data
and uncertainty in the estimated change. Our key findings
on lipid fractions were also seen where the data sources
covered the entire country or large parts of it. In 11 coun-
tries, our analysis was limited to ages 40–59 years because
fewer studies had data in people older than 60 years of age,
for whom non-HDL cholesterol may have declined more
due to the use of statins, as indicated by the results in the
10 countries with data covering ages 40–79 years.
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Whereas early epidemiological studies used TC as a
marker of cardiovascular risk in individuals and popula-
tions,72 our study shows that the populations of Asian
and Western countries have experienced large and hetero-
geneous changes in lipid fractions, including substantial
increases in HDL cholesterol and substantial falls in non-
HDL cholesterol. In the best-performing countries, those
in Europe and New Zealand, the total-to-HDL choles-
terol ratio has declined by 1.5–2.3 since the 1980s, which
is equivalent to a 48–63% reduction in the risk of CHD.1
In Japan and South Korea, the total-to-HDL cholesterol
ratio has declined, which provides a simple explanation
for the apparent paradox of declining CHD while TC in-
creased.73 A key implication of our findings is the
need for national surveillance systems that, consistently
with modern clinical practice, measure relevant lipid
fractions and their determinants, including diet, health
behaviours such as smoking and alcohol use, and use of
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statins to support the design and evaluation of public-
health programmes.
Despite the improvements that we have documented,
the populations of all countries analysed here would bene-
fit from lower non-HDL cholesterol and total-to-HDL
cholesterol ratios. In China, which had some of the lowest
recorded non-HDL cholesterol and TC levels a few decades
ago, changes in diet and relatively low treatment coverage
have led to unfavourable trends in lipid profiles. Therefore,
population-based policies and targeted interventions to im-
prove nutrition and enhance treatment are still needed in
all these countries and should be designed and evaluated
based on their impacts on all health-relevant lipid fractions
and on the corresponding health outcomes.
Supplementary data
Supplementary data are available at IJE online.
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USA); Martina Mu¨ller-Nurasyid (Helmholtz Zentrum
Mu¨nchen, Germany); Toshiharu Ninomiya (Kyushu
University, Japan); Janina Petkeviciene (Lithuanian
University of Health Sciences, Lithuania); Fernando
Rodrı´guez-Artalejo (Universidad Auto´noma de
Madrid/CIBERESP, Spain); Jennifer Servais (Statistics
Canada, Canada); Stefan So¨derberg (Umea˚ University,
Sweden); Bill Stavreski (Heart Foundation, Australia);
Tom Wilsgaard (UiT The Arctic University of
Norway, Norway); Tomasz Zdrojewski (Medical
University of Gdansk, Poland); Dong Zhao (Capital
Medical University Beijing An Zhen Hospital, China);
Gretchen A Stevens (World Health Organization,
Switzerland); Stefan Savin (World Health
Organization, Switzerland); Melanie J Cowan (World
Health Organization, Switzerland); Leanne M Riley
(World Health Organization, Switzerland); Majid
Ezzati (Imperial College London, UK)
Country and Regional Data
(* equal contribution; listed alphabetically)
Robert J Adams (The University of Adelaide,
Australia)*; Wichai Aekplakorn (Mahidol University,
Thailand)*; Wolfgang Ahrens (Leibniz Institute for
Prevention Research and Epidemiology - BIPS,
Germany)*; Philippe Amouyel (Lille University and
Hospital, France)*; Antoinette Amuzu (London
School of Hygiene & Tropical Medicine, UK)*;
Sigmund A Anderssen (Norwegian School of Sport
Sciences, Norway)*; Inger Ariansen (Norwegian
Institute of Public Health, Norway)*; Dominique
Arveiler (Strasbourg University and Hospital,
France)*; Thor Aspelund (University of Iceland,
Iceland)*; Juha Auvinen (University of Oulu,
Finland)*; Ma´ria Avdicova´ (Regional Authority of
Public Health, Banska Bystrica, Slovakia)*; Maciej
Banach (Medical University of Lodz, Poland)*; Piotr
Bandosz (Medical University of Gdansk, Poland)*;
Jose´ R Banegas (Universidad Auto´noma de Madrid,
Spain)*; Carlo M Barbagallo (University of Palermo,
Italy)*; Iqbal Bata (Dalhousie University, Canada)*;
Louise A Baur (University of Sydney, Australia)*;
Robert Beaglehole (University of Auckland, New
Zealand)*; James E Bennett (Imperial College
London, UK)*; Gailute Bernotiene (Lithuanian
University of Health Sciences, Lithuania)*; Yufang Bi
(Shanghai Jiao-Tong University School of Medicine,
China)*; Asako Bienek (Public Health Agency of
Canada, Canada)*; Cecilia Bjo¨rkelund (University of
Gothenburg, Sweden)*; Simona Bo (University of
Turin, Italy)*; Bernhard O Boehm (Nanyang
Technological University, Singapore)*; Marialaura
Bonaccio (IRCCS Neuromed, Italy)*; Vanina Bongard
(Toulouse University School of Medicine, France)*;
Rossana Borchini (University Hospital of Varese,
Italy)*; Herman Borghs (University Hospital KU
Leuven, Belgium)*; Juergen Breckenkamp (Bielefeld
University, Germany)*; Hermann Brenner (German
Cancer Research Center, Germany)*; Graziella Bruno
(University of Turin, Italy)*; Markus A Busch (Robert
Koch Institute, Germany)*; Antonio Cabrera de Leo´n
(Universidad de La Laguna, Spain)*; Vincenzo
Capuano (Cardiologia di Mercato S. Severino, Italy)*;
Felipe F Casanueva (Santiago de Compostela
University, Spain)*; Juan-Pablo Casas (University
College London, UK)*; Carmelo A Caserta
(Associazione Calabrese di Epatologia, Italy)*; Laura
Censi (Council for Agricultural Research and
Economics, Italy)*; Fangfang Chen (Capital Institute
of Pediatrics, China)*; Shuohua Chen (Kailuan
General Hospital, China)*; Marı´a-Dolores Chirlaque
(Murcia Health Council, CIBERESP, IMIB-Arrixaca,
Spain)*; Belong Cho (Seoul National University
College of Medicine, South Korea)*; Yumi Cho
(Korea Centers for Disease Control and Prevention,
South Korea)*; Jerzy Chudek (Medical University of
Silesia, Poland)*; Renata Cifkova (Charles University
in Prague, Czech Republic; Thomayer Hospital, Czech
Republic)*; Frank Claessens (Katholieke Universiteit
Leuven, Belgium)*; Janine Clarke (Statistics Canada,
Canada)*; Els Clays (Ghent University, Belgium)*;
Cyrus Cooper (University of Southampton, UK)*;
Simona Costanzo (IRCCS Neuromed, Italy)*;
Dominique Cottel (Institut Pasteur de Lille, France)*;
Chris Cowell (University of Sydney, Australia)*; Ana
B Crujeiras (CIBEROBN, Spain)*; Liufu Cui (Kailuan
General Hospital, China)*; Graziella D’Arrigo
(National Council of Research, Italy)*; Jean
Dallongeville (Institut Pasteur de Lille, France)*; Luc
Dauchet (Lille University Hospital, France)*; Guy De
Backer (Ghent University, Belgium)*; Dirk De
Bacquer (Ghent University, Belgium)*; Giovanni de
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Gaetano (IRCCS Neuromed, Italy)*; Stefaan De
Henauw (Ghent University, Belgium)*; Delphine De
Smedt (Ghent University, Belgium)*; Elaine Dennison
(University of Southampton, UK)*; Vale´rie
Deschamps (French Public Health Agency, France)*;
Augusto Di Castelnuovo (Mediterranea Cardiocentro,
Italy)*; Annette J Dobson (University of Queensland,
Australia)*; Chiara Donfrancesco (Istituto Superiore
di Sanita`, Italy)*; Angela Do¨ring (Helmholtz Zentrum
Mu¨nchen, Germany)*; Wojciech Drygas (The
Cardinal Wyszynski Institute of Cardiology, Poland)*;
Yong Du (Robert Koch Institute, Germany)*; Elzbieta
Dziankowska-Zaborszczyk (Medical University of
Lodz, Poland)*; Robert Eggertsen (University of
Gothenburg, Sweden)*; Ulf Ekelund (Norwegian
School of Sport Sciences, Norway)*; Roberto Elosua
(Institut Hospital del Mar d’Investigacions Me`diques,
Spain)*; Johan G Eriksson (National Institute for
Health and Welfare, Finland)*; Alun Evans (Queen’s
University of Belfast, UK)*; David Faeh (University of
Zurich, Switzerland)*; Francisco J Felix-Redondo
(Centro de Salud Villanueva Norte, Spain)*; Daniel
Ferna´ndez-Berge´s (Servicio Extreme~no de Salud,
Spain)*; Marika Ferrari (Council for Agricultural
Research and Economics, Italy)*; Jean Ferrieres
(Toulouse University School of Medicine, France)*;
Joseph D Finn (University of Manchester, UK)*; Ann-
Sofie Forslund (Umea˚ University, Sweden)*; Maria
Forsner (Umea˚ University, Sweden)*; Guillermo
Frontera (Hospital Universitario Son Espases, Spain)*;
Yuki Fujita (Kindai University, Japan)*; Zbigniew
Gaciong (Medical University of Warsaw, Poland)*;
Fabio Galvano (University of Catania, Italy)*; Jingli
Gao (Kailuan General Hospital, China)*; Manoli
Garcia-de-la-Hera (CIBER en Epidemiologı´a y Salud
Pu´blica, Spain)*; Sarah P Garnett (University of
Sydney, Australia)*; Jean-Michel Gaspoz (Geneva
University Hospitals, Switzerland)*; Magda Gasull
(CIBER en Epidemiologı´a y Salud Pu´blica, Spain)*;
Louise Gates (Australian Bureau of Statistics,
Australia)*; Simona Giampaoli (Istituto Superiore di
Sanita`, Italy)*; Francesco Gianfagna (University of
Insubria, Italy; Mediterranea Cardiocentro, Italy)*;
Tiffany K Gill (The University of Adelaide,
Australia)*; Jonathan Giovannelli (Lille University
Hospital, France)*; Aleksander Giwercman (Lund
University, Sweden)*; David Goltzman (McGill
University, Canada)*; Marcela Gonzalez Gross
(Universidad Polite´cnica de Madrid, Spain)*; Frederic
Gottrand (Universite´ de Lille 2, France)*; Sidsel Graff-
Iversen (Norwegian Institute of Public Health,
Norway)*; Dusan Grafnetter (Institute for clinical and
experimental medicine, Czech Republic)*; Ronald D
Gregor (Dalhousie University, Canada)*; Tomasz
Grodzicki (Jagiellonian University Medical College,
Poland)*; Giuseppe Grosso (University of Catania,
Italy)*; Gabriella Gruden (University of Turin, Italy)*;
Dongfeng Gu (National Center of Cardiovascular
Diseases, China)*; Pilar Guallar-Castillo´n
(Universidad Auto´noma de Madrid, Spain)*; Elias F
Gudmundsson (Icelandic Heart Association,
Iceland)*; Vilmundur Gudnason (University of
Iceland, Iceland)*; Idris Guessous (Geneva University
Hospitals, Switzerland)*; Johanna Gunnlaugsdottir
(Icelandic Heart Association, Iceland)*; Felix
Gutzwiller (University of Zurich, Switzerland)*;
Rebecca Hardy (University College London, UK)*;
Jun Hata (Kyushu University, Japan)*; Teresa
Haugsgjerd (University of Bergen, Norway)*; Alison J
Hayes (University of Sydney, Australia)*; Jiang He
(Tulane University, USA)*; Yuna He (Chinese Center
for Disease Control and Prevention, China)*; Sauli
Herrala (Oulu University Hospital, Finland)*; Ilpo
Tapani Hihtaniemi (Imperial College London, UK)*;
Michael Hobbs (University of Western Australia,
Australia)*; Wilma M Hopman (Kingston Health
Sciences Centre, Canada)*; Jose´ Marı´a Huerta
(CIBER en Epidemiologı´a y Salud Pu´blica, Spain)*;
Inge Huybrechts (International Agency for Research
on Cancer, France)*; Licia Iacoviello (University of
Insubria, Italy; IRCCS Neuromed, Italy)*; Anna G
Iannone (Cardiologia di Mercato S. Severino, Italy)*;
Nayu Ikeda (National Institute of Health and
Nutrition, Japan)*; Masanori Iwasaki (Niigata
University, Japan)*; Rod Jackson (University of
Auckland, New Zealand)*; Konrad Jamrozik (The
University of Adelaide, Australia; deceased)*; Imre
Janszky (Norwegian University of Science and
Technology, Norway)*; Marjo-Riitta Jarvelin
(Imperial College London, UK; University of Oulu,
Finland)*; Grazyna Jasienska (Jagiellonian University
Medical College, Poland)*; Garry Jennings (Heart
Foundation, Australia)*; Seung-lyeal Jeong (National
Health Insurance Service, South Korea)*; Chao Qiang
Jiang (Guangzhou 12th Hospital, China)*; Michel
Joffres (Simon Fraser University, Canada)*; Jari J
Jokelainen (Oulu University Hospital, Finland)*; Jost
B Jonas (Ruprecht-Karls-University of Heidelberg,
Germany)*; Jacek Jo´zwiak (University of Opole,
Poland)*; Eero O Kajantie (National Institute for
Health and Welfare, Finland)*; Jussi Kauhanen
(University of Eastern Finland, Finland)*; Ulrich Keil
(University of Mu¨nster, Germany)*; Sirkka Keina¨nen-
Kiukaanniemi (Oulu University Hospital, Finland)*;
Mathilde Kersting (Research Institute of Child
Nutrition, Germany)*; Young-Ho Khang (Seoul
National University, South Korea)*; Ursula Kiechl-
Kohlendorfer (Medical University of Innsbruck,
Austria)*; Stefan Kiechl (Medical University of
Innsbruck, Austria)*; Jeongseon Kim (National
Cancer Center, South Korea)*; Yeon-Yong Kim
(National Health Insurance Service, South Korea)*;
Jurate Klumbiene (Lithuanian University of Health
Sciences, Lithuania)*; Michael Knoflach (Medical
University of Innsbruck, Austria)*; Stephanie Ko
(Public Health Agency of Canada, Canada)*; Elin
Kolle (Norwegian School of Sport Sciences,
Norway)*; Raija Korpelainen (University of Oulu,
Finland; Oulu Deaconess Institute Foundation,
Finland)*; Seppo Koskinen (National Institute for
Health and Welfare, Finland)*; Katsuyasu Kouda
(Kindai University, Japan)*; Wolfgang Kratzer
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(University Hospital Ulm, Germany)*; Susi Kriemler
(University of Zu¨rich, Switzerland)*; Steinar Krokstad
(Norwegian university of science and technology,
Norway)*; Urho M Kujala (University of Jyva¨skyla¨,
Finland)*; Pawel Kurjata (The Cardinal Wyszynski
Institute of Cardiology, Poland)*; Kari Kuulasmaa
(National Institute for Health and Welfare, Finland)*;
Tiina Laatikainen (National Institute for Health and
Welfare, Finland)*; Tai Hing Lam (University of
Hong Kong, China)*; Vera Lanska (Institute for
Clinical and Experimental Medicine, Czech
Republic)*; Georg Lappas (Sahlgrenska Academy,
Sweden)*; Lars E Laugsand (Norwegian University of
Science and Technology, Norway)*; Jeonghee Lee
(National Cancer Center, South Korea)*; Terho
Lehtima¨ki (Tampere University Hospital, Finland;
Tampere University, Finland)*; Yanping Li (Harvard
TH Chan School of Public Health, USA)*; Christa L
Lilly (West Virginia University, USA)*; Xu Lin
(University of Chinese Academy of Sciences, China)*;
Lars Lind (Uppsala University, Sweden)*; Lauren
Lissner (Gothenburg University, Sweden)*; Jing Liu
(Capital Medical University Beijing An Zhen
Hospital, China)*; Esther Lopez-Garcia (Universidad
Auto´noma de Madrid, Spain)*; Roberto Lorbeer
(University Medicine Greifswald, Germany)*; Jose´
Eugenio Lozano (Consejerı´a de Sanidad Junta de
Castilla y Leo´n, Spain)*; Dalia Luksiene (Lithuanian
University of Health Sciences, Lithuania)*; Annamari
Lundqvist (National Institute for Health and Welfare,
Finland)*; Robert Lundqvist (Norrbotten County
Council, Sweden)*; Per Lytsy (University of Uppsala,
Sweden)*; Guansheng Ma (Peking University,
China)*; Suka Machi (The Jikei University School of
Medicine, Japan)*; Stefania Maggi (National
Research Council, Italy)*; Dianna J Magliano (Baker
Heart and Diabetes Institute, Australia)*; Jim I Mann
(University of Otago, New Zealand)*; Enzo Manzato
(University of Padova, Italy)*; Pedro Marques-Vidal
(Lausanne University Hospital, Switzerland)*; Ellisiv
B Mathiesen (UiT The Arctic University of Norway,
Norway)*; Stela McLachlan (University of Edinburgh,
UK)*; Rachael M McLean (University of Otago, New
Zealand)*; Scott B McLean (Statistics Canada,
Canada)*; Aline Meirhaeghe (Institut National de la
Sante´ et de la Recherche Me´dicale, France)*; Christa
Meisinger (Helmholtz Zentrum Mu¨nchen,
Germany)*; Patricia Metcalf (University of Auckland,
New Zealand)*; Jie Mi (Capital Institute of Pediatrics,
China)*; Jody C Miller (University of Otago, New
Zealand)*; Luis A Moreno (Universidad de Zaragoza,
Spain)*; Suzanne N Morin (McGill University,
Canada)*; Malgorzata Mossakowska (International
Institute of Molecular and Cell Biology, Poland)*;
Maria L Muiesan (University of Brescia, Italy)*;
Martina Mu¨ller-Nurasyid (Helmholtz Zentrum
Mu¨nchen, Germany)*; Jaakko Mursu (University of
Eastern Finland, Finland)*; Harunobu Nakamura
(Kobe University, Japan)*; Jana Na´mesna´ (Regional
Authority of Public Health, Banska Bystrica,
Slovakia)*; Matthias Nauck (University Medicine of
Greifswald, Germany)*; Eva Maria Navarrete-Mu~noz
(CIBER en Epidemiologı´a y Salud Pu´blica, Spain)*;
William A Neal (West Virginia University, USA)*;
Ilona Nenko (Jagiellonian University Medical College,
Poland)*; Teemu J Niiranen (National Institute for
Health and Welfare, Finland; University of Turku,
Finland)*; Guang Ning (Shanghai Jiao-Tong
University School of Medicine, China)*; Toshiharu
Ninomiya (Kyushu University, Japan)*; Marianna
Noale (National Research Council, Italy)*; Davide
Noto (University of Palermo, Italy)*; Terence O’Neill
(University of Manchester, UK)*; Dermot O’Reilly
(Queen’s University of Belfast, UK)*; Kyungwon Oh
(Korea Centers for Disease Control and Prevention,
South Korea)*; O¨rn Olafsson (Icelandic Heart
Association, Iceland)*; Fred Michel Paccaud (Institute
for social and preventive medicine, Canada)*; Andrzej
Pajak (Jagiellonian University Medical College,
Poland)*; Luigi Palmieri (Istituto Superiore di Sanita`,
Italy)*; Francesco Panza (IRCCS Casa Sollievo della
Sofferenza, Italy)*; Winsome R Parnell (University of
Otago, New Zealand)*; Markku Peltonen (National
Institute for Health and Welfare, Finland)*; Annette
Peters (Helmholtz Zentrum Mu¨nchen, Germany)*;
Astrid Petersmann (University Medicine of Greifswald,
Germany)*; Janina Petkeviciene (Lithuanian University
of Health Sciences, Lithuania)*; Iris Pigeot (Leibniz
Institute for Prevention Research and Epidemiology -
BIPS, Germany)*; Lorenza Pilotto (Cardiovascular
Prevention Centre Udine, Italy)*; Aleksandra Piwonska
(The Cardinal Wyszynski Institute of Cardiology,
Poland)*; Pedro Plans-Rubio´ (Public Health Agency
of Catalonia, Spain)*; Miquel Porta (Institut Hospital
del Mar d’Investigacions Me`diques, Spain)*; Jacqueline
F Price (University of Edinburgh, UK)*; Jardena
J Puder (Lausanne University Hospital, Switzerland)*;
Soile E Puhakka (University of Oulu; Oulu Deaconess
Institute Foundation, Finland)*; Ricardas Radisauskas
(Lithuanian University of Health Sciences, Lithuania)*;
Olli Raitakari (University of Turku, Finland)*; Rafel
Ramos (Institut Universitari d’Investigacio´ en Atencio´
Prima`ria Jordi Gol, Spain)*; Josep Redon (University
of Valencia, Spain)*; Fernando Rigo (Health Center
San Agustı´n, Spain)*; Fernando Rodrı´guez-Artalejo
(Universidad Auto´noma de Madrid/CIBERESP,
Spain)*; Marı´a del Cristo Rodriguez-Perez (Canarian
Health Service, Spain)*; Dora Romaguera
(CIBEROBN, Spain)*; Kimmo Ronkainen (University
of Eastern Finland, Finland)*; Annika Rosengren
(University of Gothenburg, Sweden)*; Joel GR Roy
(Statistics Canada, Canada)*; Jean-Bernard Ruidavets
(Toulouse University Hospital, France)*; Marcin
Rutkowski (Medical University of Gdansk, Poland)*;
Benoit Salanave (French Public Health Agency,
France)*; Diego Salmero´n (CIBER de Epidemiologı´a y
Salud Pu´blica, Spain)*; Veikko Salomaa (National
Institute for Health and Welfare, Finland)*; Jukka T
Salonen (University of Helsinki, Finland)*; Massimo
Salvetti (University of Brescia, Italy)*; Susana Sans
(Catalan Department of Health, Spain)*; Jouko L
Saramies (South Karelia Social and Health Care
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District, Finland)*; Kai-Uwe Saum (German Cancer
Research Center, Germany)*; Norie Sawada (National
Cancer Center, Japan)*; Christa Scheidt-Nave (Robert
Koch Institute, Germany)*; Anja Schienkiewitz
(Robert Koch Institute, Germany)*; Sabine Schipf
(University Medicine of Greifswald, Germany)*;
Carsten O Schmidt (University Medicine of Greifswald,
Germany)*; Ben Scho¨ttker (German Cancer Research
Center, Germany)*; Sylvain Sebert (University of Oulu,
Finland)*; Abhijit Sen (Norwegian University of Science
and Technology, Norway)*; Jennifer Servais (Statistics
Canada, Canada)*; Jonathan E Shaw (Baker Heart
and Diabetes Institute, Australia)*; Kenji Shibuya
(King’s College London, UK)*; Dong Wook Shin
(Sungkyunkwan University, South Korea)*; Rahman
Shiri (Finnish Institute of Occupational Health,
Finland)*; Judith Simons (St Vincent’s Hospital,
Australia)*; Leon A Simons (University of New South
Wales, Australia)*; Michael Sjo¨stro¨m (Karolinska
Institutet, Sweden)*; Jolanta Slowikowska-Hilczer
(Medical University of Lodz, Poland)*; Przemyslaw
Slusarczyk (International Institute of Molecular and
Cell Biology, Poland)*; Stefan So¨derberg (Umea˚
University, Sweden)*; Vincenzo Solfrizzi (University of
Bari, Italy)*; Emily Sonestedt (Lund University,
Sweden)*; Aicha Soumare (University of Bordeaux,
France)*; Jan A Staessen (University of Leuven,
Belgium)*; Maria G Stathopoulou (INSERM, France)*;
Bill Stavreski (Heart Foundation, Australia)*; Jostein
Steene-Johannessen (Norwegian School of Sport
Sciences, Norway)*; Peter Stehle (Bonn University,
Germany)*; Jutta Stieber (Helmholtz Zentrum
Mu¨nchen, Germany; deceased)*; Doris Sto¨ckl
(Helmholtz Zentrum Mu¨nchen, Germany)*; Jakub
Stokwiszewski (National Institute of Public Health-
National Institute of Hygiene, Poland)*; Johan
Sundstro¨m (Uppsala University, Sweden)*; Paibul
Suriyawongpaisal (Mahidol University, Thailand)*;
Abdonas Tamosiunas (Lithuanian University of
Health Sciences, Lithuania)*; Eng Joo Tan (University
of Sydney, Australia)*; Anne Taylor (The University
of Adelaide, Australia)*; Grethe Tell (University of
Bergen, Norway)*; Lutgarde Thijs (University of
Leuven, Belgium)*; Hanna K Tolonen (National
Institute for Health and Welfare, Finland)*; Roman
Topo´r-Madry (Jagiellonian University Medical
College, Poland)*; Marı´a Jose´ Tormo (Health Service
of Murcia, Spain)*; Maties Torrent (IB-SALUT Area
de Salut de Menorca, Spain)*; Shoichiro Tsugane
(National Cancer Center, Japan)*; Tomi-Pekka
Tuomainen (University of Eastern Finland, Finland)*;
Jaakko Tuomilehto (National Institute for Health and
Welfare, Finland)*; Christophe Tzourio (University of
Bordeaux, France)*; Hannu MT Uusitalo (University
of Tampere Tays Eye Center, Finland)*; Koen Van
Herck (Ghent University, Belgium)*; Dirk
Vanderschueren (Katholieke Universiteit Leuven,
Belgium)*; Diego Vanuzzo (Cardiovascular
Prevention Centre Udine, Italy)*; Lars Vatten
(Norwegian University of Science and Technology,
Norway)*; Tomas Vega (Consejerı´a de Sanidad Junta
de Castilla y Leo´n, Spain)*; Giovanni Veronesi
(University of Insubria, Italy)*; Jesus Vioque
(Universidad Miguel Hernandez, Spain)*; Jyrki K
Virtanen (University of Eastern Finland, Finland)*;
Sophie Visvikis-Siest (INSERM, France)*; Peter
Vollenweider (Lausanne University Hospital,
Switzerland)*; Sari Voutilainen (University of Eastern
Finland, Finland)*; Martine Vrijheid (ISGlobal Centre
for Research in Environmental Epidemiology,
Spain)*; Aline Wagner (University of Strasbourg,
France)*; Anne Wagner (National Institute for Health
and Welfare, Finland)*; Ming-Dong Wang (Health
Canada, Canada)*; Qian Wang (Xinjiang Medical
University, China)*; Ya Xing Wang (Capital Medical
University, China)*; S Goya Wannamethee
(University College London, UK)*; Wenbin Wei
(Capital Medical University, China)*; Peter H
Whincup (St George’s, University of London, UK)*;
Andrzej Wiecek (Medical University of Silesia,
Poland)*; Johann Willeit (Medical University of
Innsbruck, Austria)*; Peter Willeit (Medical
University of Innsbruck, Austria)*; Tom Wilsgaard
(UiT The Arctic University of Norway, Norway)*;
Bogdan Wojtyniak (National Institute of Public
Health-National Institute of Hygiene, Poland)*;
Andrew Wong (University College London, UK)*;
Mark Woodward (University of New South Wales,
Australia; University of Oxford, UK)*; Frederick C
Wu (University of Manchester, UK)*; Shouling Wu
(Kailuan General Hospital, China)*; Haiquan Xu
(Institute of Food and Nutrition Development of
Ministry of Agriculture, China)*; Liang Xu (Beijing
Institute of Ophthalmology, China)*; Weili Yan
(Children’s Hospital of Fudan University, China)*;
Xiaoguang Yang (Chinese Center for Disease Control
and Prevention, China)*; Xingwang Ye (University of
Chinese Academy of Sciences, China)*; Akihiro
Yoshihara (Niigata University, Japan)*; Sabina
Zambon (University of Padova, Italy)*; Tomasz
Zdrojewski (Medical University of Gdansk, Poland)*;
Dong Zhao (Capital Medical University Beijing An
Zhen Hospital, China)*; Wenhua Zhao (Chinese
Center for Disease Control and Prevention, China)*
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